Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Legend Biotech CorporationNASDAQ: LEGN

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 187M shares rose 3.7% year over year, ahead of the +1.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +5.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.7% holds above the trailing-twelve-month pace of +1.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
187M+0.0% QoQ
Last fiscal yearDec 2025
184.32M+0.8% YoY
LTMSep 2026
185.87M+1.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.7%——
1 year+0.8%——
3-year CAGR+5.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
184.32M USD
Year-over-year change
+0.8%
4-year CAGR
+7.0%

Weighted Avg Shares vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 weighted avg shares of 185.87M shares is the 3rd highest of the 11 companies compared; the peer median is 90.32M shares.
  • Its year-over-year change of +1.7% is the 9th highest of 11, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of +5.0% compares with a peer median of +22.8%.
LEGN Competitors Peer median
Weighted Avg Shares for LEGN and competitors
Company Period LTM YoY 3-year CAGR
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
RNACCartesian Therapeutics, Inc.LTM Mar 202626.2M +16.5%+86.2%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.1M +49.4%+45.4%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
Peer median (excluding LEGN) 90.32M+6.8%+22.8%

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.83M117.01M285.14M627.24M1.03B
Cost of Revenue065.36M144.21M234.58M408.1M
Gross Profit68.83M51.64M140.93M392.66M620.8M
Gross Margin100.0%44.1%49.4%62.6%60.3%
Research & Development313.35M335.65M382.22M413.54M414.7M
Selling, General & Admin149.5M174.05M200.93M284.26M341.6M
Operating Expenses461.11M507.26M580.41M695.9M757.3M
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
EBITDA(392.38M)(416.54M)(477.87M)(113.16M)(232.3M)
EBITDA Margin-570.1%-356.0%-167.6%-18.0%-22.6%
Operating Income(392.29M)(455.62M)(439.49M)(303.24M)(136.5M)
Operating Margin-570.0%-389.4%-154.1%-48.3%-13.3%
Interest Income971K8.18M54.49M61.2M40.1M
Interest Expense900K10.8M21.79M21.62M21.4M
Other Income / Expenses(14.91M)9.9M(80.63M)145.11M(146.1M)
Income Before Tax(407.2M)(445.72M)(520.12M)(158.13M)(282.6M)
Pre-Tax Margin-591.6%-380.9%-182.4%-25.2%-27.5%
Income Tax Expense(3.61M)625K(1.86M)18.89M14.2M
Net Income(403.58M)(446.35M)(518.25M)(177.03M)(296.8M)
Net Margin-586.4%-381.5%-181.8%-28.2%-28.8%
EPS (Basic)(2.74)(2.81)(2.94)(0.97)(1.60)
EPS (Diluted)(2.74)(2.81)(2.94)(0.97)(1.60)
Weighted Avg Shares140.85M159.04M176.08M182.85M184.32M
Weighted Avg Shares (Diluted)140.85M159.04M176.08M182.85M184.32M

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.